Immunovant (IMVT) Prices $550 Million Offering to Fund Anti-FcRn Pipeline Development
Immunovant (IMVT) priced a $550 million stock offering to fund clinical trials for IMVT-1402 and batoclimab across multiple autoimmune indications.